The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | J | Antiinfectives for systemic use | |
| 2 | J05 | Antivirals for systemic use | |
| 3 | J05A | Direct acting antivirals | |
| 4 | J05AR | Antivirals for treatment of HIV infections, combinations | |
| 5 | J05AR10 |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.8 mg |
| Active Ingredient | Description | |
|---|---|---|
| Lopinavir and Ritonavir |
Lopinavir provides the antiviral activity of lopinavir/ritonavir. Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. Inhibition of HIV protease prevents cleavage of the gag-pol polyprotein resulting in the production of immature, non-infectious virus. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| KALETRA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| KALETRA Oral solution | European Medicines Agency (EU) | MPI, EU: SmPC | |
| RILOVIA Film-coated tablet | Health Products Regulatory Authority (ZA) | MPI, Generic |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
